Despite decades of research, no CMV vaccine has been approved to date, underscoring the importance of these new discoveries ... With our AI-Immunology™ platform, we have uncovered novel antigens that are entirely new to the CMV vaccine research field.
Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1. Evaxion's AI-Immunology™ platform has discovered novel CMV antigens that significantly reduce viral infection in preclinical models.
CMV-Specific CD4+ and CD8+ T-Cell Responses to 2- and 3-Dose mRNA-1647 Schedules Through 12 Months Among (A) CMV-Seronegative and ... CMV infection3,4 ... Schedules Through 12 Months Among CMV-Seronegative (A) and CMV-Seropositive Participants (B).
) Today, we announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, our investigational cytomegalovirus (CMV) vaccine.
Cytomegalovirus (CMV) is associated with substantial morbidity and mortality in immunocompromised patients, including allogeneic hematopoietic cell transplantation (HCT) recipients ... mRNA-1647- An Investigational CMV Vaccine ... CMV PCR monitoring.
"Cytomegalovirus (CMV) InfectionPipeline 2025" ... DelveInsight reports that over 15 pharmaceutical and biotech companies are actively advancing more than 20 therapeutic candidates targeting CMV infection ... Cytomegalovirus (CMV) Infection Overview..